|
Easily Publish Gorgeous Magazines with Scoop.it.
Catch attention on what matters by curating content on your favorite topic. |
See How |
Skin cancer is the most common type of cancer in the United States. The tumor suppressor PTEN has been found to play a key role in radiation damage repair.
|
Brian Shields shared this post on Twitter. (August 1, 2011 9:25 PM) |
Biomarkers and Personalized Medicine
|
Introduction: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers to prospectively identify tyrosine kinase inhibitor (TKI)-sensitive patients, particularly after a previous chemotherapy treatment, is currently under debate. 
Interesting discussion regarding collaboration of biomarker research data. 
Memorial Sloan-Kettering Cancer Center (MSKCC) and IBM have announced an agreement to collaborate on the development of a powerful tool built upon IBM (RT @KurzweilAINews: Applying Watson technology for personalized cancer care: Memorial Sloan-Kettering... 
Interesting new data links VEGF signaling to the prognosis in Lung Cancer patients. 
This NYT article by John Markoff explains part of the story on why we are now sequencing entire genomes for hundreds of dollars, and why a full sequen... 
Aetna Announces Appearance at 2012 World Biomarkers ConsortiumBusiness Wire (press release)(BUSINESS WIRE)--Aetna (NYSE: AET) announced today that Dr.
"There haven't been studies that have compared the different anti-angiogenic agents, and in terms of biomarker responses or of predictive markers of which patient..." 
Dr.Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing... 
"Whole-exome sequencing reads only those parts of the human genome that encode proteins, leaving the other 99 percent of the genome unread..." 
This article highlights the power of the internet to help drive future biomarker research and drug discovery...Incredible innovation using very low cost tools Very interesting commentary on the costs that consumers continue to bear for our drugs, even when the R&D costs are contained through efficiencies of new technologies, 
This is a great example of local innovation by a diagnostics company and a local hospital to prevent failure rates of anti-infective therapies. Great quote from the article by a practitoner: "Within a day, I have at my fingertips all the information I need to directly target the organism causing infection and to stop unnecessary, broad spectrum antibiotics with their associated side effects, toxicity and health care costs," infectious disease specialist Dr. Catherine Bacheller said. Interesting analysis which may serve as a valuable tool for future research and treatment development |
Pub Med Abstract on VEGF in lung cancer. 
MGH researchers report that women with vulvar carcinoma whose tumors have extra copies of the EGFR gene are at increased risk of dying from their cancer, information that could indentify patients who should be treated with targeted therapy drugs. 
Geneticist's 'personalized medicine' study focuses on himselfVancouver SunPhysicians talk often about “personalized medicine”: the idea that therapies should be tailored to each patient's unique genetic and medical profile. 
Now, a life changing advancement in human gene sequencing has taken place. Bill Banyai, who is employed by Complete Genomics as an optical physicist, has helped develop a gene sequencing machine. These machines ...
The
nanotubes change their electrical resistance when a protein lands on them, and the extent of this change can be measured to determine the presence of a particular protein... 
Team of researchers from Cincinnati Children's Hospital has identified a biomarker that may be used to develop blood tests for a common food allergy.
Next-Generation DNA Sequencing to Improve Diagnosis for Muscular DystrophyScience Daily (press release)5, 2012) — Scientists at The University of Nottingham have used a revolutionary new DNA-reading technology for a research project that could lead... 
Dr. Mayumi Fujita and Dr. Charles Dinarello of the University Of Colorado School Of Medicine have identified a novel biomarker known as IL-37, and developed a method for the diagnosis, prognosis, and monitoring of ... Selventa contracted with Johnson & Johnson's Janssen R&D group to support their drug discovery efforts through computational methods. Selventa analyzes loads of molecular data on patients in order to help researchers understand the key drivers for a particular illness. Article highlights the dangers of counterfeit medicines for high priced agents in the global community. 
Interesting article identifying an acquired muatation causing resistance to treatment with cetuximab for patients with colorectal cancer. The article also notes that one patient responded to subsequent treatment with panitumumab. Article Excerpt: "By modeling acquired resistance to the EGFR antibody cetuximab in metastatic colorectal cancer, the authors identify a new mutation in the ectodomain of the receptor." 
This is a very good article and I love the graphic. Matthew Herper from Forbes just published a related article entitled, " The Truly Staggering Cost of Inventing New Drugs"http://www.forbes.com/sites/matthewherper/2012/02/22/the-truly-staggering-cost-of-inventing-new-drugs-the-print-version/ The cost of new drugs may be a result of this flawed approach of creating "one size fits all" medicines. Even as pharma companies thrived with this approach, the drugs they have provided to us have only been effective for limited groups of people. Therefore, in order for a patient to get the right drug, they needed to survive through multiple trials of drugs, multiple side effects, and failed attempts to improve their underlying condition. Personalized medicine is a huge step forward, but not neceassarily a step forward for drug company profits. These companies have made billions while consumers bore the risk for drugs that were not designed for their specific genetic profile or disease. This article answers the question as to why drug research costs are so high. Drug companies have been designing drugs in a shotgun approach in order to capture a large subset of potential patients---and a large subset of patients whom will fail on their drugs. Apparently, designing drugs that will fail in large percentages of patients may be more profitable than designing tailored therapies for limited groups of patients with a high rate of success. |
| 1 | 2 | 3 | 4 |  |
26 |
|
Next |
